UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2015 UpToDate®

Initial management of low-risk gestational trophoblastic neoplasia

Authors
Ross S Berkowitz, MD
Donald Peter Goldstein, MD
Neil S Horowitz, MD
Section Editor
Barbara Goff, MD
Deputy Editors
Sandy J Falk, MD, FACOG
Don S Dizon, MD, FACP

INTRODUCTION

Gestational trophoblastic disease (GTD) defines a group of conditions that arise from an aberrant fertilization event. When GTD recurs or there is evidence of metastatic disease, it is called gestational trophoblastic neoplasia (GTN) and comprises four subtypes of disease:

Invasive mole

Choriocarcinoma

Placental site trophoblastic tumor (PSTT)

Epithelioid trophoblastic tumor (ETT)

                         

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: May 2015. | This topic last updated: Jan 8, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2015 UpToDate, Inc.
References
Top
  1. McNeish IA, Strickland S, Holden L, et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol 2002; 20:1838.
  2. Sita-Lumsden A, Short D, Lindsay I, et al. Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000-2009. Br J Cancer 2012; 107:1810.
  3. Lurain JR. Pharmacotherapy of gestational trophoblastic disease. Expert Opin Pharmacother 2003; 4:2005.
  4. Alazzam M, Tidy J, Hancock BW, et al. First-line chemotherapy in low-risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev 2012; 7:CD007102.
  5. Alazzam M, Tidy J, Osborne R, et al. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev 2012; 12:CD008891.
  6. Garner EI, Feltmate CM, Goldstein DP, Berkowitz RS. The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey. Gynecol Oncol 2005; 99:3.
  7. van Trommel NE, Massuger LF, Verheijen RH, et al. The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey. Gynecol Oncol 2005; 99:6.
  8. Pezeshki M, Hancock BW, Silcocks P, et al. The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. Gynecol Oncol 2004; 95:423.
  9. Osborne RJ, Fillaci VL,Mamel RS, et al. A phase II study to determine the reponse to second curettage as initial management of persistent “low-risk” non-metastatic gestational trophoblastic neoplasia: a Gynecologoc Oncology Group study. Presented at the 2014 Annual Meeting on Women’s Cancer. LBA 2
  10. Berkowitz RS, Goldstein DP, Bernstein MR. Ten year's experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Gynecol Oncol 1986; 23:111.
  11. Berkowitz RS, Goldstein DP, Bernstein MR. Methotrexate infusion and folinic acid in the primary therapy of nonmetastatic gestational trophoblastic tumors. Gynecol Oncol 1990; 36:56.
  12. Garrett AP, Garner EO, Goldstein DP, Berkowitz RS. Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience. J Reprod Med 2002; 47:355.
  13. Wong LC, Choo YC, Ma HK. Methotrexate with citrovorum factor rescue in gestational trophoblastic disease. Am J Obstet Gynecol 1985; 152:59.
  14. Shah NT, Barroilhet L, Berkowitz RS, et al. A cost analysis of first-line chemotherapy for low-risk gestational trophoblastic neoplasia. J Reprod Med 2012; 57:211.
  15. Bagshawe KD, Dent J, Newlands ES, et al. The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). Br J Obstet Gynaecol 1989; 96:795.
  16. Khan F, Everard J, Ahmed S, et al. Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects. Br J Cancer 2003; 89:2197.
  17. HERTZ R, LEWIS J Jr, LIPSETT MB. Five year's experience with the chemotherapy of metastatic choriocarcinoma and related trophoblastic tumors in women. Am J Obstet Gynecol 1961; 82:631.
  18. Hammond CB, Borchert LG, Tyrey L, et al. Treatment of metastatic trophoblastic disease: good and poor prognosis. Am J Obstet Gynecol 1973; 115:451.
  19. Hammond CB, Hertz R, Ross GT, et al. Primary chemotherapy for nonmetastatic gestational trophoblastic neoplasms. Am J Obstet Gynecol 1967; 98:71.
  20. Lurain JR, Elfstrand EP. Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors. Am J Obstet Gynecol 1995; 172:574.
  21. Chapman-Davis E, Hoekstra AV, Rademaker AW, et al. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy. Gynecol Oncol 2012; 125:572.
  22. Homesley HD, Blessing JA, Schlaerth J, et al. Rapid escalation of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. Gynecol Oncol 1990; 39:305.
  23. Homesley HD, Blessing JA, Rettenmaier M, et al. Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstet Gynecol 1988; 72:413.
  24. Wong LC, Ngan HY, Cheng DK, Ng TY. Methotrexate infusion in low-risk gestational trophoblastic disease. Am J Obstet Gynecol 2000; 183:1579.
  25. Growdon WB, Wolfberg AJ, Goldstein DP, et al. Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia. Gynecol Oncol 2009; 112:353.
  26. Smith EB, Weed JC Jr, Tyrey L, Hammond CB. Treatment of nonmetastatic gestational trophoblastic disease: results of methotrexate alone versus methotrexate--folinic acid. Am J Obstet Gynecol 1982; 144:88.
  27. ROSS GT, GOLDSTEIN DP, HERTZ R, et al. SEQUENTIAL USE OF METHOTREXATE AND ACTINOMYCIN D IN THE TREATMENT OF METASTATIC CHORIOCARCINOMA AND RELATED TROPHOBLASTIC DISEASES IN WOMEN. Am J Obstet Gynecol 1965; 93:223.
  28. ROSS GT, STOLBACH LL, HERTZ R. Actinomycin D in the treatment of methotrexate-resistant trophoblastic disease in women. Cancer Res 1962; 22:1015.
  29. Osathanondh R, Goldstein DP, Pastorfide GB. Actinomycin D as the primary agent for gestational trophoblastic disease. Cancer 1975; 36:863.
  30. Twiggs LB. Pulse actinomycin D scheduling in nonmetastatic gestational trophoblastic neoplasia: cost-effective chemotherapy. Gynecol Oncol 1983; 16:190.
  31. Petrilli ES, Twiggs LB, Blessing JA, et al. Single-dose actinomycin-D treatment for nonmetastatic gestational trophoblastic disease. A prospective phase II trial of the Gynecologic Oncology Group. Cancer 1987; 60:2173.
  32. Petrilli ES, Morrow CP. Actinomycin D toxicity in the treatment of trophoblastic disease: a comparison of the five-day course to single-dose administration. Gynecol Oncol 1980; 9:18.
  33. Schlaerth JB, Morrow CP, Nalick RH, Gaddis O Jr. Single-dose actinomycin D in the treatment of postmolar trophoblastic disease. Gynecol Oncol 1984; 19:53.
  34. Grunberg SM, Warr D, Gralla RJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art. Support Care Cancer 2011; 19 Suppl 1:S43.
  35. Kohorn EI. Decision making for chemotherapy administration in patients with low-risk gestational trophoblastic neoplasia. Int J Gynecol Cancer 1996; 6:279.
  36. Lertkhachonsuk AA, Israngura N, Wilailak S, Tangtrakul S. Actinomycin d versus methotrexate-folinic acid as the treatment of stage I, low-risk gestational trophoblastic neoplasia: a randomized controlled trial. Int J Gynecol Cancer 2009; 19:985.
  37. Osborne RJ, Filiaci V, Schink JC, et al. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol 2011; 29:825.
  38. Matsui H, Iitsuka Y, Seki K, Sekiya S. Comparison of chemotherapies with methotrexate, VP-16 and actinomycin-D in low-risk gestational trophoblastic disease. Remission rates and drug toxicities. Gynecol Obstet Invest 1998; 46:5.
  39. Hitchins RN, Holden L, Newlands ES, et al. Single agent etoposide in gestational trophoblastic tumours. Experience at Charing Cross Hospital 1978-1987. Eur J Cancer Clin Oncol 1988; 24:1041.
  40. Wong LC, Choo YC, Ma HK. Primary oral etoposide therapy in gestational trophoblastic disease. An update. Cancer 1986; 58:14.
  41. Mangili G, Garavaglia E, Frigerio L, et al. Management of low-risk gestational trophoblastic tumors with etoposide (VP16) in patients resistant to methotrexate. Gynecol Oncol 1996; 61:218.
  42. Rustin GJ, Newlands ES, Lutz JM, et al. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol 1996; 14:2769.
  43. Savage P, Cooke R, O'Nions J, et al. Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause. J Clin Oncol 2015; 33:472.
  44. Pedersen-Bjergaard J, Daugaard G, Hansen SW, et al. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 1991; 338:359.
  45. Sung HC, Wu PC, Yang HY. Reevaluation of 5-fluorouracil as a single therapeutic agent for gestational trophoblastic neoplasms. Am J Obstet Gynecol 1984; 150:69.
  46. Song HZ, Yang XY, Xiang Y. Forty-five year's experience of the treatment of choriocarcinoma and invasive mole. Int J Gynaecol Obstet 1998; 60 Suppl 1:S77.
  47. Osborne R, Gerulath A. What is the best regimen for low-risk gestational trophoblastic neoplasia? A review. J Reprod Med 2004; 49:602.
  48. Jones WB, Cardinale C, Lewis JL Jr. Management of high-risk gestational trophoblastic disease--the Memorial Hospital experience. Int J Gynecol Cancer 1997; 7:27.
  49. Lybol C, Sweep FC, Harvey R, et al. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Gynecol Oncol 2012; 125:576.
  50. Golfier F, Labrousse C, Frappart L, et al. [Evaluation of treatment relating to gestational trophoblastic tumor registered to the French Trophoblastic Disease Reference Center (TDRC) in Lyon from 1999 to 2005]. Gynecol Obstet Fertil 2007; 35:205.
  51. van Trommel NE, Massuger LF, Schijf CP, et al. Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease. J Clin Oncol 2006; 24:52.
  52. You B, Pollet-Villard M, Fronton L, et al. Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias. Ann Oncol 2010; 21:1643.
  53. Kerkmeijer LG, Thomas CM, Harvey R, et al. External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease. Br J Cancer 2009; 100:979.
  54. Garner EI, Lipson E, Bernstein MR, et al. Subsequent pregnancy experience in patients with molar pregnancy and gestational trophoblastic tumor. J Reprod Med 2002; 47:380.
  55. Lorigan PC, Sharma S, Bright N, et al. Characteristics of women with recurrent molar pregnancies. Gynecol Oncol 2000; 78:288.
  56. Committee on Practice Bulletins-Gynecology, American College of Obstetricians and Gynecologists. ACOG Practice Bulletin #53. Diagnosis and treatment of gestational trophoblastic disease. Obstet Gynecol 2004; 103:1365.
  57. Society of Gynecologic Oncologists Clinical Practice Guidelines. Practice guidelines: gestational trophoblastic disease. Oncology (Williston Park) 1998; 12:455.
  58. Mutch DG, Soper JT, Babcock CJ, et al. Recurrent gestational trophoblastic disease. Experience of the Southeastern Regional Trophoblastic Disease Center. Cancer 1990; 66:978.
  59. Costa HL, Doyle P. Influence of oral contraceptives in the development of post-molar trophoblastic neoplasia--a systematic review. Gynecol Oncol 2006; 100:579.
  60. Kim JH, Park DC, Bae SN, et al. Subsequent reproductive experience after treatment for gestational trophoblastic disease. Gynecol Oncol 1998; 71:108.
  61. Ayhan A, Ergeneli MH, Yüce K, et al. Pregnancy after chemotherapy for gestational trophoblastic disease. J Reprod Med 1990; 35:522.
  62. Amr MF. Return of fertility after successful chemotherapy treatment of gestational trophoblastic tumors. Int J Fertil Womens Med 1999; 44:146.
  63. Vargas R, Barroilhet LM, Esselen K, et al. Subsequent pregnancy outcomes after complete and partial molar pregnancy, recurrent molar pregnancy, and gestational trophoblastic neoplasia: an update from the New England Trophoblastic Disease Center. J Reprod Med 2014; 59:188.
  64. Braga A, Maestá I, Michelin OC, et al. Maternal and perinatal outcomes of first pregnancy after chemotherapy for gestational trophoblastic neoplasia in Brazilian women. Gynecol Oncol 2009; 112:568.
  65. Van Thiel DH, Ross GT, Lipsett MB. Pregnancies after chemotherapy of trophoblastic neoplasms. Science 1970; 169:1326.
  66. Ngan HY, Wong LC, Ma HK. Reproductive performance of patients with gestational trophoblastic disease in Hong Kong. Acta Obstet Gynecol Scand 1988; 67:11.
  67. Song HZ, Wu PC, Wang YE, et al. Pregnancy outcomes after successful chemotherapy for choriocarcinoma and invasive mole: long-term follow-up. Am J Obstet Gynecol 1988; 158:538.
  68. Kjer J, Iverson T. Malignant trophoblastic tumors in Norway: Fertility rate after chemotherapy. Br J Obstet Gynecol 1990; 97:623.
  69. Woolas RP, Bower M, Newlands ES, et al. Influence of chemotherapy for gestational trophoblastic disease on subsequent pregnancy outcome. Br J Obstet Gynaecol 1998; 105:1032.
  70. Lok CA, van der Houwen C, ten Kate-Booij MJ, et al. Pregnancy after EMA/CO for gestational trophoblastic disease: a report from The Netherlands. BJOG 2003; 110:560.
  71. Matsui H, Iitsuka Y, Suzuka K, et al. Early pregnancy outcomes after chemotherapy for gestational trophoblastic tumor. J Reprod Med 2004; 49:531.
  72. Goldstein DP, Zanten-Przybysz IV, Bernstein MR, Berkowitz RS. Revised FIGO staging system for gestational trophoblastic tumors. Recommendations regarding therapy. J Reprod Med 1998; 43:37.
  73. Sebire NJ, Fisher RA, Foskett M, et al. Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy. BJOG 2003; 110:22.
  74. Williams J, Short D, Dayal L, et al. Effect of early pregnancy following chemotherapy on disease relapse and fetal outcome in women treated for gestational trophoblastic neoplasia. J Reprod Med 2014; 59:248.
  75. Cagayan MS, Llarena RT. Quality of life of gestational trophoblastic neoplasia survivors: a study of patients at the Philippine General Hospital trophoblastic disease section. J Reprod Med 2010; 55:321.
  76. Wenzel L, Berkowitz RS, Newlands E, et al. Quality of life after gestational trophoblastic disease. J Reprod Med 2002; 47:387.
  77. Horowitz NS, Wenzel LB. Psychosocial consequences of gestational trophoblastic disease. In: Getational Trophoblastic Disease, 3rd edition, BW Hancock, MJ Seckl, RS Berkowitz, L Cole. (Eds), Wiley, Sheffield, UK 2009. p.460.
  78. Goldstein DP, Garner EI, Feltmate CM, Berkowitz RS. The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. Gynecol Oncol 2004; 95:421.
  79. Schlaerth JB, Morrow CP, Rodriguez M. Diagnostic and therapeutic curettage in gestational trophoblastic disease. Am J Obstet Gynecol 1990; 162:1465.
  80. Goldstein DP, Berkowitz RS. Current management of gestational trophoblastic neoplasia. Hematol Oncol Clin North Am 2012; 26:111.
  81. Papadopoulos AJ, Foskett M, Seckl MJ, et al. Twenty-five years' clinical experience with placental site trophoblastic tumors. J Reprod Med 2002; 47:460.
  82. Feltmate CM, Genest DR, Goldstein DP, Berkowitz RS. Advances in the understanding of placental site trophoblastic tumor. J Reprod Med 2002; 47:337.
  83. Palmer JE, Macdonald M, Wells M, et al. Epithelioid trophoblastic tumor: a review of the literature. J Reprod Med 2008; 53:465.
  84. Shen X, Xiang Y, Guo L, et al. Fertility-preserving treatment in young patients with placental site trophoblastic tumors. Int J Gynecol Cancer 2012; 22:869.
  85. Gamer EI, Garrett A, Goldstein DP, Berkowitz RS. Significance of chest computed tomography findings in the evaluation and treatment of persistent gestational trophoblastic neoplasia. J Reprod Med 2004; 49:411.
  86. Ngan HY, Chan FL, Au VW, et al. Clinical outcome of micrometastasis in the lung in stage IA persistent gestational trophoblastic disease. Gynecol Oncol 1998; 70:192.
  87. Clark RM, Nevadunsky NS, Ghosh S, et al. The evolving role of hysterectomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. J Reprod Med 2010; 55:194.
  88. Roberts JP, Lurain JR. Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy. Am J Obstet Gynecol 1996; 174:1917.
  89. Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol 2009; 112:654.
  90. Soper JT. Surgical therapy for gestational trophoblastic disease. J Reprod Med 1994; 39:168.
  91. Yang J, Xiang Y, Wan X, Yang X. The prognosis of gestational trophoblastic neoplasia patient with residual lung tumor after completing treatment. Gynecol Oncol 2006; 103:479.